The COVID-19 Pandemic wreaked havoc on many businesses. For others, though, it created new opportunities to sell to the federal government, including an unprecedented demand for personal protective equipment (“PPE”), COVID tests, and vaccines. Perhaps your company found itself as a first-time government contractor, or you started selling products to the government that you had never sold before. If your government contract went smoothly, congratulations! If not, you may be left wondering who will pay for unexpected increased costs of performance, or how you can defend against the government’s claims to recoup overpayments or liquidated damages.
About
Keeley McCarty is an associate in the Governmental Practice in the firm's Washington, D.C. office.
Latest Post
More Posts
A Second Chance to Win Your Government Healthcare Contract
Organizational Conflicts of Interest – Part 3: The Next Target for FCA Enforcement
The Government Seeks FCA Liability for Off-Label Use of Medical Devices
The Government Seeks FCA Liability for Off-Label Use of Medical Devices
Supreme Court Enjoins OSHA Emergency Temporary Standard; Keeps CMS Rule Alive
Health Law Policy Heading Into 2022 At The ABA Health Law Summit
MSPV 2.0 Is Dead – Long Live MSPV
Authorized Government Contractors Now Covered Persons Under the PREP Act
“Would You Rather…” – Escobar’s Demanding Materiality Standard or Actual Causation?
Navigating FDA Policies for PPE, and Liability Protections
Not So Fast – FDA Retracts Authorization for Some Respirators Made in China
Not So Fast – FDA Retracts Authorization for Some Respirators Made in China
PREP Act Update: All NIOSH-Approved Respirators Now Are Covered Countermeasures Eligible for Immunity
COVID-19 Changes Contracting at the VA
About
Keeley McCarty is an associate in the Governmental Practice in the firm's Washington, D.C. office.